These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14737055)

  • 41. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
    Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
    J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia.
    Cappozzo C
    Oncol Nurs Forum; 2004 May; 31(3):569-76. PubMed ID: 15146222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: an observational retrospective survey.
    Repetto L;
    Crit Rev Oncol Hematol; 2009 Nov; 72(2):170-9. PubMed ID: 19406660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
    Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
    Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
    Tuffaha HW; Treish IM; Zaru L
    J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of febrile neutropenia episodes in children with acute leukemia treated with BFM protocols.
    Yilmaz S; Oren H; Demircioğlu F; Irken G
    Pediatr Hematol Oncol; 2008; 25(3):195-204. PubMed ID: 18432502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
    Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
    Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
    Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH
    Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [G-CSF in patients with lupus-associated neutropenia and infections].
    Schwab UM; Harten P; Zeuner RA; Külper M; Euler HH
    Z Rheumatol; 1996; 55(3):174-9. PubMed ID: 8768147
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meropenem +/- granulocyte colony stimulating factor in the treatment of febrile neutropenic patients with cancer: prospective randomized study.
    Er O; Coskun HS; Altinbas M; Ozkan M; Eser B; Cetin M; Altuntas F; Unal A
    J Chemother; 2004 Jun; 16(3):288-92. PubMed ID: 15330327
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Effectiveness of Leukostim, a Russian preparation of granulocyte colony-stimulating factor, in the treatment of chemotherapy-induced neutropenia in patients with malignant tumors].
    Korman DB; Boronovskaia LE; Maslova IA; Andreeva EV; Seregina GV
    Vopr Onkol; 2008; 54(5):639-42. PubMed ID: 19069482
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer.
    Borg C; Ray-Coquard I; Philip I; Clapisson G; Bendriss-Vermare N; Menetrier-Caux C; Sebban C; Biron P; Blay JY
    Cancer; 2004 Dec; 101(11):2675-80. PubMed ID: 15503313
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal timing (Preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide.
    Koumakis G; Vassilomanolakis M; Barbounis V; Hatzichristou E; Demiri S; Plataniotis G; Pamouktsoglou F; Efremidis AP
    Oncology; 1999; 56(1):28-35. PubMed ID: 9885374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists.
    Danova M; Rosti G; De Placido S; Bencardino K; Venturini M
    Oncol Rep; 2005 Dec; 14(6):1405-12. PubMed ID: 16273232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effective G-CSF therapy strategies for cyclical neutropenia: mathematical modelling based hypotheses.
    Foley C; Bernard S; Mackey MC
    J Theor Biol; 2006 Feb; 238(4):754-63. PubMed ID: 16115650
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
    Crea F; Giovannetti E; Zinzani PL; Danesi R
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Granulocyte colony-stimulating factor in neutropenic, pediatric solid tumor patients following chemotherapy.
    Ayan I; Kebudi R; Doğan S; Tokuç G; Görgün O
    Pediatr Hematol Oncol; 1996; 13(5):417-24. PubMed ID: 10897813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.